for FERROVIR drug
Registry Number: Р N000630/01
Trade name: Ferrovir.
Chemical name: Complex of Sodium deoxyribonucleate with Ferrum
Pharmaceutical dosage form: solution for intramuscular introduction.
Active Ingredient/Active Moiety : Complex of Sodium deoxyribonucleate with Ferrum - 75,24 мг
Inactive Ingredients : water for injection up to 5 ml
Product Characteristics : Clear yellow liquid.
Pharmacotherapeutic Group: Immunomodulating and antiviral drug.
ATC Code: JO5ACh.
Ferrovir is a biologically active substance derived from milt of sturgeon or salmon (refined and standardized complex salt of natrium deoxyribonucleat and ferrum).The drug has antiviral and immunomodulating effect, it activates antiviral, antimycotic and antimicrobial immunity. It make antiviral effect against various RNA- and DNA-containing viruses. The drug clinical use has proved its high efficacy, high tolerance level, no toxicity (IC50>4000mkg/ml) and no unwanted side-effects. Monotherapy of AIDS/HIV-infection, in fourteen-day used of Ferrovir demonstrated the increases CD4+lymphocytes concentration in the blood. The concentration continues increasing within 1-1.5 months after the termination of the course of treatment. Reported is lower of viral load which is evidenced by HIV RNA concentration decrease, if compared to the initial level. For recurrent herpetic infection, ten-day course of treatment leads to decrease in severity of recurrence and to reduction of its continuance, and quick and prolonged remission occurs. Ferrovir application for the complex treatment of chronic C-hepatitis patients contributes to the improvement of the treatment tolerance (reduction of vertigo and nausea, etc.) and decreasing of the replicative activity for all HCV-virus genotypes, as well as to the process conversion into latent phase with complete recovery of hepatocytes and interruption of the viral replication. The drug demonstrates a high activity rate in both: a primary infection, and an opportunistic virus disease. The drug chemotherapeutic index exceeds 20 that are typical for high-active drugs.
When the recommended dose is introduced intramuscularly, the drug is absorbed fast and distributed within organs and tissues via endolymphatic transportation way. This drug is high-tropic to hematopoietic system organs, and it actively participates in cell metabolism process regulation, and specific interact with the cell structures. During daily course application it can be cumulated in organs and tissues. Maximum concentration at single introduction is reached in 30 minutes, and then the drug concentration in blood decreases which happens due to the drug distribution within organs and tissues. At multiple-dose introduction every 24 hours during 4 days, maximum drug accumulation can be observed in spleen, lymph nodes and bone marrow. The drug concentration in all organs and tissues does not increase with every further introduction after the 5th injection; on the contrary, gradual concentration decrease is observed.
Metabolism and excretion
The drug is excreted from organism (as metabolites) mainly with urine and partially with faeces. Average time of drug persistence within organs and tissues is 72 hrs. Semi excretion time is 36 hrs.
Indications for application
Ferrovir is used for combined therapeutic treatment of HIV- and AIDS-patients, HIV-patients with C-hepatitis, HIV-patients with recurrent herpetic infection, as well as for the treatment of tick-borne encephalitis patients, C-hepatitis patients and herpetic patients.
Hypersensitivity to the active substance or to any other component of the drug, children under 18 years.
Do not use this drug during pregnancy
Breastfeeding is not recommended in patients receiving Ferrovir.
and during breastfeeding
Dosage and mode of administration
For the treatment of HIV-infection or AIDS, the drug is prescribed to adults intramuscularly: 5 ml (15 mg/ml) of the solution for intramuscular introduction (75 mg on a dry basis) twice a day (150 mg) during 14 days. If necessary, the 2nd therapeutic course can be prescribed 1-1.5 months after the 1st one.
For herpes treatment: 5 ml (15 mg/ml) of the solution for intramuscular introduction, twice a day during 10 days.
For C-hepatitis treatment, 5 ml (15 mg/ml) of Ferrovir solution for intramuscular introduction is introduced intramuscularly twice a day during 14 days. In the following 14 days, the same daily dose of the drug is introduced every second day.
For tick-borne encephalitis treatment, 5 ml (15 mg/ml) solution of Ferrovir for intramuscular introduction is introduced twice a day during 5-10 days.
Possible short-time fever (body temperature can increase up to 38°С), hyperemia and painfulness at the injection site.
A negative consequence of overdosing was not reported.
Lightly potentiates anticoagulant activity.
In complex therapy, reduces toxicity and negative effect of the drugs prescribed (headache, nausea, etc.).
In order to make the injection less painful, Ferrovir is slowly introduced intramuscularly within 1-2 minutes.
The solution for injection should be entirely used immediately upon the bottle opening; keeping open bottles is not allowed.
Intravenous introduction of the drug is not allowed!
Influence on the ability to drive vehicles, mechanisms.
The effect of the drug on the ability to drive vehicles or moving machinery is not marked.
Solution for intramuscular injection of 15 mg / ml.
5 ml in bottles of 5 ml of colorless or brown glass, hermetically sealed with rubber stoppers and rolled around with aluminum caps with a tear-off plastic pad Flip off, in a contour plastic package (pallet) in a cardboard bundle No. 5
Keep in a shadowed place at a temperature range from +4°С to +20ºС. Save away from children.
5 years. Do not use after the expiration of validity period which is indicated on the package.
Pharmacy purchasing terms
The drug is only available on prescription
LLC Immunoleks Pharmaceutical Plant
Russia 105318, Russia, Moscow, Mironovskaya street 33, bldg 27,
Market Authorization Holder.
127521, Russia, Moscow, Annensky passage, home ownership 7, bldg 1.,Tel.: (495) 739-52-98, (495) 739-52-03, website: www.derinat.com
Director of PharmPack LLC, Valery Yu. Kaplin
Official website: www.ferrovir.ru
- Instructions. Medication Guide for FERROVIR drug
- R&D. Derinat Protects Skin against Ultraviolet-B (UVB)-Induced Cellular Damage
- R&D. The significance of immunomodulatory therapy in pregravidal preparation of the patients with recurrent HSV type 2
- R&D. The probable mechanism of reparative effect of eukaryotic DNA oligonucleotides as agonists Toll-like receptors 9 on the model of drug Derinat